Reply 2: NICE guidelines on drugs for colorectal cancer
2003
Response to NICE Guidelines on Colorectal Cancer Drugs
publication
Author Information
Author(s): Ross P J, D Cunningham
Primary Institution: Royal Marsden Hospital
Conclusion
Access to all three drugs for treating metastatic colorectal cancer is crucial for optimal patient outcomes.
Supporting Evidence
- Patients not in the FOCUS trial will receive suboptimal therapy.
- The median survival for FOCUS is 16 months, which is better than previous treatments.
Takeaway
Doctors think patients with advanced colorectal cancer need three specific medicines to get better, and if they don't have access to all three, they might not do as well.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website